Log In
Print this Print this

oral plasma kallikrein inhibitors

  Manage Alerts
Collapse Summary General Information
Company KalVista Pharmaceuticals Ltd.
DescriptionOral plasma kallikrein inhibitors
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetic macular edema (DME)
Indication DetailsTreat diabetic macular edema (DME)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today